


Amendments to the Claims

1. (Currently Amended) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;



wherein ;

~~R<sub>1</sub> is selected from groups (a), (b), and (c) wherein;~~

~~———— (a) is C<sub>7</sub>-C<sub>20</sub> alkyl, C<sub>7</sub>-C<sub>20</sub> haloalkyl, C<sub>7</sub>-C<sub>20</sub> alkenyl, C<sub>7</sub>-C<sub>20</sub> alkynyl, carbocyclic radical, or heterocyclic radical, or~~

~~———— (b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or~~


~~(c) is the group -(L<sub>1</sub>)-R<sub>11</sub>; where, -(L<sub>1</sub>)- is a divalent linking group of~~

~~1 to 8 atoms and where R<sub>11</sub> is a group selected from (a)-~~



~~or (b) is -(CH<sub>2</sub>)<sub>m</sub>-R<sub>12</sub>;~~

~~R<sub>2</sub> is hydrogen, or C<sub>1</sub>-C<sub>4</sub> alkyl a group containing 1 to 4 non-hydrogen atoms plus any required hydrogen atoms;~~


~~R<sub>3</sub> is -(L<sub>3</sub>)- Z, where -(L<sub>3</sub>)- is a divalent linker group selected from a bond or a divalent group selected from:~~



and Z is selected from a group represented by the formulae,



or



wherein, X is oxygen or sulfur; and R<sub>a</sub> is selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkaryl, C<sub>1</sub>-C<sub>8</sub> alkoxy, aralkyl and -CN;


R<sub>4</sub> is the group, -(L<sub>h</sub>)-(hydroxyfunctional amide); wherein -(L<sub>h</sub>)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;

R<sub>5</sub> is selected from hydrogen, a non-interfering substituent, or the group, -(L<sub>a</sub>)-(acidic group); wherein -(L<sub>a</sub>)-, is an acid linker having an acid linker length of 1 to 8;

R<sub>6</sub> and R<sub>7</sub> are selected from hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, and C<sub>2</sub>-C<sub>6</sub> alkynyl; ~~non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted with non-interfering substituent(s).~~






2. (Currently Amended) The compound of claim 1 wherein R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, -O-(C<sub>1</sub>-C<sub>3</sub> alkyl), -S-(C<sub>1</sub>-C<sub>3</sub> alkyl), and C<sub>3</sub>-C<sub>4</sub> cycloalkyl, ~~CF<sub>3</sub>, halo, NO<sub>2</sub>, CN, or SO<sub>3</sub>.~~

3. (Original) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L<sub>h</sub>)-, for R<sub>4</sub> is selected from a group represented by the formula;




where Q<sub>2</sub> is selected from the group -(CH<sub>2</sub>)-, -O-, -NH-, -C(O)-, and -S-, and each R<sub>40</sub> is independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, C<sub>1</sub>-C<sub>8</sub> alkaryl, C<sub>1</sub>-C<sub>8</sub> alkoxy, aralkyl, and halo.

4. (Currently Amended) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L<sub>h</sub>)-, for R<sub>4</sub> is a divalent group selected from,



or






where R<sub>40</sub>, R<sub>41</sub>, R<sub>42</sub>, and R<sub>43</sub> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl.


5. (Canceled)

6. (Currently Amended) The compound of claim 1 wherein R<sub>5</sub> is the group, -  
(L<sub>a</sub>)-(acidic group) and wherein the (acidic group) is ~~selected from the group:~~

~~-5-tetrazolyl,~~

~~-SO<sub>3</sub>H,~~






where  $R_{80}$  is a metal or  $C_1$ - $C_8$  alkyl and  $R_{81}$  is an organic substituent or  $-CF_3$ .

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Original) The compound of claim 1 wherein for  $R_3$ , Z is the group represented by the formula;



and the linking group  $-(L_3)-$  is a bond.

11. (Canceled)

12. (Canceled)

13. (Canceled)


14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Original) The compound of claim 1 wherein  $R_4$  is the group,  $-(L_c)-$  (hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and  $R^{4a}$  is independently selected from the group consisting of OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>7</sub>-C<sub>14</sub>)alkaryloxy, (C<sub>2</sub>-C<sub>8</sub>)alkenyloxy, (C<sub>7</sub>-C<sub>14</sub>) aralkyloxy, (C<sub>7</sub>-C<sub>14</sub>)aralkenyloxy and aryloxy; and

wherein R<sup>4b</sup> is independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, arylalkyl, heteroaryl and aryl.

19. (Canceled)

20. (Original) A compound of claim 1 selected from the group consisting of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)-N-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)-N-(2-propyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-[2-(methyl)propyloxy]acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(cyclohexyl)-N-(hydroxy)acetamide; and



2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)acetamide.

21. (Canceled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Original) A method of inhibiting sPLA<sub>2</sub> mediated release of fatty acid comprising: contacting sPLA<sub>2</sub> with a therapeutically effective amount of indole compound as claimed in claim 1.

24. (Currently Amended) A method of treating a mammal, ~~including a human,~~ to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises administering to said mammal a thrapeutically effective amount of an indole compound as claimed in Claim 1.

25. (Currently Amended) A ~~compound of claim 1 or~~ a pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Canceled)

27. (Canceled)